Objectives This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs.
warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories …

Oral anticoagulation is obligatory in patients with atrial fibrillation (AF) to prevent
thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety …

Background Current evidence suggests that rivaroxaban may be well tolerated and effective
in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited …

Background There are limited data regarding clinical outcomes and healthcare resource
utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are …

Highlights•Obesity is an important risk factor for atrial fibrillation.•Despite “obesity paradox”
in atrial fibrillation, patient weight loss preferred.•Oral anticoagulants may be more …

Background Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide and the main
cause of anticoagulation, being direct oral anticoagulants (DOAC) increasingly used in this …

The prevalence of both atrial fibrillation (AF) and obesity has steadily increased. Nonvitamin
K antagonist oral anticoagulants (NOACs) have been shown to be more effective and safer …

Background Considering that the current fixed dose of direct oral anticoagulants (DOACs)
might have insufficient anticoagulation effect for overweight patients, the aim of this study …

Objectives Obesity is associated with increased risks of atrial fibrillation (AF) and venous
thromboembolism (VTE) for which anticoagulation is commonly used. However, data on the …